<HashMap><database>ENA</database><scores/><additional><omics_type>Genomics</omics_type><center_name>Experimental Immunology IFReC, Osaka university</center_name><full_dataset_link>https://www.ebi.ac.uk/ena/browser/view/PRJDB18080</full_dataset_link><scientific_name>Mammalia</scientific_name><long_description>One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T cells (Tconvs) into Foxp3+ regulatory T cells (Tregs) as stably suppressive as naturally occurring Tregs (nTregs). To achieve the conversion in vitro in mice and humans, we induced high Foxp3 expression in antigen- and IL-2-stimulated Tconvs by CDK8/19 inhibition, and installed Treg-specific epigenetic changes in Treg signature genes, especially Foxp3, by depriving CD28 co-stimulation during the Treg induction. Repeating this process, with intermittent resting cultures solely with IL-2, enabled efficient conversion of naÃ¯ve as well as effector/memory CD4+ Tconvs, including Th1, Th2 and Th17 cells, into Foxp3+ Tregs transcriptionally and epigenetically similar to nTregs. Tregs thus induced were indeed functionally and phenotypically stable in vivo and effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory Tconv-derived, functionally stable, induced Tregs can be instrumental in antigen- and disease-specific treatment of immunological diseases.</long_description><repository>ENA</repository></additional><is_claimable>false</is_claimable><name>Mammalia</name><description>In vitro induction of antigen-specific and functionally stable Treg cells from effector/memory conventional T cells for adoptive cell therapy of immunological diseases</description><dates><last_updated>2025-09-08</last_updated><first_public>2025-09-08</first_public></dates><accession>PRJDB18080</accession><cross_references><taxon>40674</taxon></cross_references></HashMap>